Compounds > pazelliptine
Page last updated: 2024-12-06

pazelliptine

Description

pazelliptine: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68853
CHEMBL ID40124
SCHEMBL ID62441
MeSH IDM0082280

Synonyms (37)

Synonym
nsc-303565
5h-pyrido[3',5]pyrrolo[2,3-g]isoquinoline, 1,3-propanediamine deriv.
nsc303565
ellipticine deriv, pasteur
1, n,n-diethyl-n'-(6-methyl-5h-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl)-
65222-35-7
sr-95225b
bd-40
nsc-327471d
pazelliptine
nsc-629464j
nsc 303565
10-((3-(diethylamino)propyl)amino)-6-methyl-5h-pyrido(3',4':4,5)pyrrolo(2,3-g)isoquinoline
brn 0571979
n,n-diethyl-n'-(6-methyl-5h-pyrido(3',4':4,5)pyrrolo(2,3-g)isoquinolin-10-yl)propane-1,3-diamine
pazelliptinum [latin]
pazeliptina [spanish]
pazelliptine [inn]
einecs 265-640-7
1,3-propanediamine, n,n-diethyl-n'-(6-methyl-5h-pyrido(3',4':4,5)pyrrolo(2,3-g)isoquinolin-10-yl)-
pazellipticine
CHEMBL40124
sr 95225
sr-95225
pazelliptinum
pazeliptina
2csp4u82hk ,
unii-2csp4u82hk
SCHEMBL62441
bd40
n,n-diethyl-n-(6-methyl-5h-pyrido[3,4:4,5]pyrrolo[2,3-g]isoquinolin-10-yl)propane-1,3-diamine
pazelliptine; sr 95225; nsc 303565
Q27254566
n',n'-diethyl-n-(2-methyl-6,13,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),2,4,6,8,11(16),12,14-octaen-7-yl)propane-1,3-diamine
DTXSID00867130
n~1~,n~1~-diethyl-n~3~-(6-methyl-5h-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl)propane-1,3-diamine
n,n-diethyl-n'-(6-methyl-5h-pyrido[3',4'
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID225212Tested for the change in body weight between day1 and 7 for murine solid tumor model C26 early stage that is subcutaneously implanted by the intravenous treatment at the dose of 10 mg/kg in 1-4 schedule1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.
AID228628Tested for medium tumor weight of treated /control animals x 100 (% T/C) for murine solid tumor model B16 early stage that is subcutaneously implanted by the intravenous treatment at the dose of 5 mg/kg in 1-4 schedule1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.
AID97886Cytotoxicity against L1210 tumor cell line, activity is expressed as K (inverse value of drug concentration)1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID225216Tested for medium tumor weight of treated /control animals x 100 (% T/C) for murine solid tumor model MA 16/C early stage that is subcutaneously implanted by the intravenous treatment at the dose of 5 mg/kg in 1-4 schedule1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.
AID225215Tested for the change in body weight between day1 and 7 for murine solid tumor model MA 16/C early stage that is subcutaneously implanted by the intravenous treatment at the dose of 5 mg/kg in 1-4 schedule1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.
AID96801In vitro cytotoxicity against L1210 cell line as concentration required for 50% inhibition of cell growth1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID154582In vivo T/C (survival time treated/survival time control x 100) was determined against P388 leukemia cells at 10 mg/Kg1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.
AID225210Tested for medium tumor weight of treated /control animals x 100 (% T/C) for murine solid tumor model C26 early stage that is subcutaneously implanted by the intravenous treatment at the dose of 10 mg/kg in 1-4 schedule1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.
AID98986Antitumor activity against L1210 leukemia cells measured as range of death at 20 mg/kg; value may range from 14 to 251983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID96956Antitumor activity against L1210 leukemia cells measured as percent increase in life span (% ILS) at 10 mg/kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID228629Tested for the change in body weight between day1 and 7 for murine solid tumor model B16 early stage that is subcutaneously implanted by the intravenous treatment at the dose of 5 mg/kg in 1-4 schedule1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.
AID98442Antitumor activity against L1210 leukemia cells measured as Median survival time at 20 mg/kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID212887Acute toxicity in mice (LD100) after i.p. administration1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID212886Acute toxicity in mice (LD0) after i.p. administration (highest nontoxic dose)1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (57.89)18.7374
1990's8 (42.11)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.36 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		1.9610acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		2.6630indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		1.9810aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
nalidixic acid
[no description available]		1.98101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
thymidine
[no description available]		1.9610pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		1.9810delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
sodium azide
Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).		1.9610inorganic sodium saltantibacterial agent;
explosive;
mitochondrial respiratory-chain inhibitor;
mutagen
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		1.9610pseudohalide anionmitochondrial respiratory-chain inhibitor
diaziquone
diaziquone: RN given refers to parent cpd. diaziquone : A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups.		1.98101,4-benzoquinones;
aziridines;
carbamate ester;
enamine		alkylating agent;
antineoplastic agent
intoplicine
intoplicine: structure in first source		2.3920pyridoindole
retelliptine
retelliptine: structure given in first source; SR-95325 B (NSC-D626717) is the dihydrochloride		2.8940
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		1.9610actinomycinmutagen
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		1.9810carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Leukemia
[description not available]		01.9710
Leukemia L 1210
[description not available]		02.6530
Abnormalities, Autosome
[description not available]		01.9810
Anemia, Fanconi
[description not available]		01.9810
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		01.9810
chemdatabank.com